Table III.
Association of PRR11 expression and the clinicopathological characteristics of the PCa in two cohorts.
| Taylor cohort | Our cohort | |||||
|---|---|---|---|---|---|---|
| N | Mean ± SD | P-value | Low | High | P-value | |
| Age (years) | ||||||
| <70 | 144 | 5.25±0.36 | 0.330 | |||
| ≥70 | 6 | 5.62±0.83 | ||||
| Preoperative PSA (ng/ml) | ||||||
| <4 | 25 | 5.27±0.44 | 0.674 | |||
| ≥4 | 122 | 5.24±0.32 | ||||
| Gleason score | ||||||
| <8 | 117 | 5.18±0.27 | 0.013 | |||
| ≥8 | 22 | 5.50±0.54 | ||||
| Clinical stage | ||||||
| <T2A | 80 | 5.21±0.31 | 0.182 | |||
| ≥T2A | 65 | 5.28±0.39 | ||||
| Pathological stage | ||||||
| T2A-T2C | 86 | 5.17±0.25 | 0.012 | 26 | 34 | 0.008 |
| T3A-T4 | 55 | 5.33±0.42 | 14 | 52 | ||
| Metastasis | ||||||
| Negative | 122 | 5.17±0.23 | <0.001 | |||
| Positive | 28 | 5.70±0.60 | ||||
| Biochemical recurrence | ||||||
| Negative | 104 | 5.16±0.23 | 0.003 | |||
| Positive | 36 | 5.42±0.48 | ||||
| Overall survival | ||||||
| Alive | 131 | 5.21±0.31 | 0.007 | |||
| Died | 19 | 5.66±0.63 | ||||
| Tissue type | ||||||
| Cancer | 150 | 5.27±0.39 | <0.001 | 41 | 85 | <0.001 |
| Benign | 29 | 5.09±0.14 | 18 | 4 | ||
PSA, prostate-specific antigen.